NSCLC Survival Model in a Chemonaive Patient - Medical Algorithm

Are you evaluating a patient with non-small cell lung carcinoma ?

Yes

Has the patient received previous chemo-therapy for the lung cancer?

Yes

Has the patient had lung surgery for the tumor?

Yes

Has the patient experienced a loss of appetite?

Yes

Total number of metastatic sites

Does the patient have liver metastases?

Yes

Does the patient have skin or subcutaneous tissue metastases?

Yes

Select an appropriate answer for each finding

ECOG performance status

Tumor stage

Results

Please fill out required fields.

Results Interpretation and Description References Next Steps

Data complete?

Evaluation appropriate?

Total points

Probability of 1 year survival

Probability of 2 year survival

MedicalAlgorithms.com APIs

Power Your Solutions with 5,000+ Automated Medical Analytics

Seamlessly integrate our API library of over 5,000 evidence-based medical analytics into your products and workflows. Our APIs help you:

Build custom, automated clinical workflows tailored to your organization's needs.
Enhance your clinical decision support with advanced, evidence-based analytics.
Streamline revenue cycle management by integrating clinical analytics into billing, coding, and compliance processes.
Support payment and pre-approval processes with automated, standardized medical criteria.
Embed proven medical algorithms directly into your systems and services for consistent, high-quality outcomes.

With MedicalAlgorithms.com APIs, you can accelerate innovation, improve efficiency, and deliver more accurate, data-driven care—without reinventing the wheel.

Explore Medal API

Caution: A qualified health practitioner should verify all results.
Keep patient data confidential and comply with all legal requirements.

Please visit our website Medicalalgorithms.com for Description and Interpretation and further algorithms you may want to consider in the next steps of your evaluation. All information should be verified by a qualified health professional, and all use is subject to Medicalalgorithms.com Terms and Conditions. © Copyright Medicalalgorithms.com Limited

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Risk Factors
- Risk Factors for Lung Cancer
Imaging Studies
- False-Positive & False-Negative Findings for Lung Cancer Associated with Positron Emission Tomography (PET)
Laboratory Tests
- Circulating Tumor Cells (CTC) in Patient with Lung Cancer
- Detection of EGFR Mutation in Non-Small Cell Lung Carcinoma Using Immunohistochemistry (IHC)
Other Testing
- Detection of EGFR Mutation in Non-Small Cell Lung Carcinoma Using Immunohistochemistry (IHC)
Severity, Prognosis, Stage
Complications
- Paraneoplastic Syndromes Seen in Patients with Lung Cancer

Therapy

Options
- Molecular Testing of Lung Adenocarcinoma | EGFR Mutation Testing
Selection
- Small Cell Lung Cancer | Pretreatment Prognostic Score

Evaluation

Results

Please fill out required fields.

MedicalAlgorithms.com APIs

Power Your Solutions with 5,000+ Automated Medical Analytics

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Therapy

Specialty

Objective

ICD-10

Model of Hoang et al for Predicting Survival in a Chemonaive Patient with Advanced Non Small Cell Lung Cancer Treated with Platinum-Based Doublet Chemotherapy

Purpose: To predict survival after chemotherapy in a patient with a non-small cell lung cancer based on the study of Hoang et al.

Evaluation

Results

Please fill out required fields.

MedicalAlgorithms.com APIs

Power Your Solutions with 5,000+ Automated Medical Analytics

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Therapy

Specialty

Objective

ICD-10